Dr. Vivek Bhalla, MD
Nephrology (Kidney) (Nephrology Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Diego School of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 166
Licensed in California since 1999, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of California, San Diego School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
CA license A70125 (first issued 1999; current) -
Internal Medicine Physician
CA license A70125 (first issued 1999; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 166
- Services billed
- 362
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 129 | 80 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 118 | 60 |
| Established patient office or other outpatient visit, 20-29 minutes | 48 | 37 |
| Established patient office or other outpatient visit, 30-39 minutes | 42 | 33 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 31 | 31 |
| Hemodialysis procedure with physician evaluation | 30 | 17 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 27 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 22 | 19 |
| Established patient office or other outpatient visit, 10-19 minutes | 19 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 41 payments worth $22,091 in total to this clinician.
| Medtronic, Inc. | $10,769 |
|---|---|
| Idorsia Pharmaceuticals US Inc | $5,766 |
| AstraZeneca Pharmaceuticals LP | $5,557 |
| Consulting Fee | $17,530 |
|---|---|
| Travel and Lodging | $3,452 |
| Food and Beverage | $1,109 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Medtronic, Inc. Oct 1, 2025 | Consulting Fee SYMPLICITY G3 · Renal Denervation System | $7,916 |
| Idorsia Pharmaceuticals US Inc Jun 19, 2025 | Consulting Fee TRYVIO · Hypertension | $4,865 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,499 |
| AstraZeneca Pharmaceuticals LP Oct 1, 2025 | Consulting Fee | $1,200 |
| AstraZeneca Pharmaceuticals LP Dec 6, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $800 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionResearch Related Service | $796 |
| Idorsia Pharmaceuticals US Inc Jun 19, 2025 | Travel and Lodging TRYVIO · Hypertension · travel to Chicago, IL · in-kind | $653 |
| Medtronic, Inc. Jul 10, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $619 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionResearch Related Service | $460 |
| Medtronic, Inc. May 7, 2025 | Consulting Fee SYMPLICITY G3 · Renal Denervation System | $425 |
All 22 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 6, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $800 |
| AstraZeneca Pharmaceuticals LP Dec 4, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $400 |
| Medtronic, Inc. Oct 1, 2025 | Consulting Fee SYMPLICITY G3 · Renal Denervation System | $7,916 |
| AstraZeneca Pharmaceuticals LP Oct 1, 2025 | Consulting Fee | $1,200 |
| Medtronic, Inc. Sep 3, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $43.51 |
| Medtronic, Inc. Aug 28, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $29.80 |
| Medtronic, Inc. Aug 27, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $139 |
| Medtronic, Inc. Aug 26, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $179 |
| Medtronic, Inc. Aug 26, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $28.68 |
| Medtronic, Inc. Aug 26, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $28.34 |
| Medtronic, Inc. Aug 25, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $179 |
| Medtronic, Inc. Aug 25, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $28.68 |
| Medtronic, Inc. Jul 10, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $619 |
| Medtronic, Inc. Jul 10, 2025 | Travel and Lodging SYMPLICITY G3 · Renal Denervation System · travel to Minneapolis, MN · in-kind | $4.68 |
| Idorsia Pharmaceuticals US Inc Jun 19, 2025 | Consulting Fee TRYVIO · Hypertension | $4,865 |
| Idorsia Pharmaceuticals US Inc Jun 19, 2025 | Travel and Lodging TRYVIO · Hypertension · travel to Chicago, IL · in-kind | $653 |
| Medtronic, Inc. May 16, 2025 | Consulting Fee SYMPLICITY G3 · Renal Denervation System | $425 |
| Medtronic, Inc. May 7, 2025 | Consulting Fee SYMPLICITY G3 · Renal Denervation System | $425 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,499 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionResearch Related Service | $796 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionResearch Related Service | $460 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionResearch Related Service | $263 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $48,544 in research payments for these studies, mostly to the institutions running them.
- A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with R…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.